All In Biotech

Drug Trial Radar · NCT05283226

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Sep 30, 2022

Primary completion

Dec 30, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
NATCO Pharma Ltd.Industry
Sponsor type
Industry
First posted
Mar 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.

Conditions

  • Carcinoma
  • Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

  • NRC-2694-ADrug

    300 mg orally once daily

  • PaclitaxelDrug

    175 mg/m² IV infusion over approximately 3 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine if NRC-2694-A administered orally in combination with paclitaxel demonstrates objective response in patients with R/M HNSCC, who have had radiological progression on or after treatment with ICI therapies like pembrolizumab or nivolumabTime frame: Baseline through approximately up to 24 weeks

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Providence Medical Foundation -Fullerton

    Fullerton, California · Completed

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California · Completed

  • Lynn Cancer Center

    Boca Raton, Florida · Completed

  • Miami Cancer Center

    Miami, Florida · Completed

  • Norton Cancer Institute - Downtown

    Louisville, Kentucky · Completed

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland · Completed

  • Washington University - Siteman Cancer Center

    St Louis, Missouri · Completed

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire · Completed

  • Salib Oncology

    Easton, Pennsylvania · Completed

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin · Completed

  • Daycare Angels under AOH

    Mumbai, Maharashtra, India · Recruiting

  • Grant Medical Foundation Ruby Hall Clinic

    Pune, Maharashtra, India · Completed

  • Basavatarakam Indo American Cancer Hospital & Research Institute

    Hyderabad, Telangana, India · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.